<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33440924</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1592-8721</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>107</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Haematologica</Title>
          <ISOAbbreviation>Haematologica</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden.</ArticleTitle>
        <Pagination>
          <StartPage>457</StartPage>
          <EndPage>466</EndPage>
          <MedlinePgn>457-466</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2020.271106</ELocationID>
        <Abstract>
          <AbstractText>Pediatric-onset Evans syndrome (pES) is defined by both immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA) before the age of 18 years. There have been no comprehensive long-term studies of this rare disease, which can be associated to various immunopathological manifestations (IM). We report outcomes of the 151 patients with pES and more than 5 years of follow-up from the nationwide French prospective OBS'CEREVANCE cohort. Median age at final follow-up was 18.5 years (range, 6.8-50.0 years) and the median follow-up period was 11.3 years (range, 5.1-38.0 years). At 10 years, ITP and AIHA were in sustained complete remission in 54.5% and 78.4% of patients, respectively. The frequency and number of clinical and biological IM increased with age: at the age of 20 years, 74% had at least one clinical IM (cIM). A wide range of cIM occurred, mainly lymphoproliferation, dermatological, gastrointestinal/hepatic and pneumological IM. The number of cIM was associated with a subsequent increase in the number of second-line treatments received (other than steroids and immunoglobulins; hazard ratio 1.4, 95% Confidence Interval: 1.15-1.60, P=0.0002, Cox proportional hazards method). Survival at 15 years after diagnosis was 84%. Death occurred at a median age of 18 years (range, 1.7-31.5 years), and the most frequent cause was infection. The number of second-line treatments and severe/recurrent infections were independently associated with mortality. In conclusion, long-term outcomes of pES showed remission of cytopenias but frequent IM linked to high second-line treatment burden. Mortality was associated to drugs and/or underlying immunodeficiencies, and adolescents-young adults are a high-risk subgroup.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pincez</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux, France; Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Department of Pediatrics, Sainte-Justine University Hospital, Université de Montréal, Montréal, Québec.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fernandes</LastName>
            <ForeName>Helder</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux, France; Pediatric Oncology Hematology Unit, University Hospital, Plurithématique CIC (CICP), Centre d'Investigation Clinique (CIC) 1401, INSERM Bordeaux.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leblanc</LastName>
            <ForeName>Thierry</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Hematology Unit, Robert Debré University Hospital, AP-HP, Paris.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Michel</LastName>
            <ForeName>Gérard</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology, La Timone Hospital, Marseille University Hospital, Marseille.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barlogis</LastName>
            <ForeName>Vincent</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology, La Timone Hospital, Marseille University Hospital, Marseille.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bertrand</LastName>
            <ForeName>Yves</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pediatric Hematology and Oncology, Lyon University Hospital, Lyon.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neven</LastName>
            <ForeName>Bénédicte</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Immuno-Hematology and Rheumatology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris, France; Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Paris, France; Imagine Institute, UMR 1163 INSERM and Paris University, Paris.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chahla</LastName>
            <ForeName>Wadih Abou</ForeName>
            <Initials>WA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology, Jeanne de Flandre Hospital, Lille University Hospital, Lille.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pasquet</LastName>
            <ForeName>Marlène</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Oncology Immunology Hematology Unit, Children's University Hospital, Toulouse.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guitton</LastName>
            <ForeName>Corinne</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Bicêtre University Hospital, AP-HP, Le Kremlin-Bicêtre.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marie-Cardine</LastName>
            <ForeName>Aude</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology and Oncology, Rouen University Hospital, Rouen.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pellier</LastName>
            <ForeName>Isabelle</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Unit, Angers University Hospital, Angers.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Armari-Alla</LastName>
            <ForeName>Corinne</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Oncology Hematology Unit, Grenoble University Hospital, Grenoble.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benadiba</LastName>
            <ForeName>Joy</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hemato-Oncology Pediatric, Nice University Hospital, Nice.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blouin</LastName>
            <ForeName>Pascale</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology-Oncology, Clocheville Hospital, Tours University Hospital, Tours.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeziorski</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Oncology Hematology Unit, Arnaud de Villeneuve University Hospital, Montpellier.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Millot</LastName>
            <ForeName>Frédéric</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology, Poitiers University Hospital, Poitiers.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paillard</LastName>
            <ForeName>Catherine</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology and Oncology, Hautepierre University Hospital, Strasbourg.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>Caroline</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Hematology Unit, Nantes University Hospital, Nantes.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheikh</LastName>
            <ForeName>Nathalie</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology-Oncology, Besanc_on University Hospital, Besanc_on.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bayart</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Hematology Unit, Rennes University Hospital, Rennes.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fouyssac</LastName>
            <ForeName>Fanny</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Hematology Unit, Nancy University Hospital, Nancy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piguet</LastName>
            <ForeName>Christophe</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Oncology Hematology Unit, Limoges University Hospital, Limoges.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deparis</LastName>
            <ForeName>Marianna</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Oncology-Hematology Unit Department, Caen University Hospital, Caen.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Briandet</LastName>
            <ForeName>Claire</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Dijon University Hospital, Dijon.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dore</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Unit, Clermont-Ferrand University Hospital, Clermont-Ferrand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Picard</LastName>
            <ForeName>Capucine</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Imagine Institute, UMR 1163 INSERM and Paris University, Paris, France; Study Center for Primary Immunodeficiencies, Necker-Enfants Malades University Hospital, AP-HP, Paris.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rieux-Laucat</LastName>
            <ForeName>Frédéric</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Paris, France; Imagine Institute, UMR 1163 INSERM and Paris University, Paris.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Landman-Parker</LastName>
            <ForeName>Judith</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Oncology Immunology Hematology Unit, Armand-Trousseau University Hospital, AP-HP, Paris.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leverger</LastName>
            <ForeName>Guy</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Oncology Immunology Hematology Unit, Armand-Trousseau University Hospital, AP-HP, Paris.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aladjidi</LastName>
            <ForeName>Nathalie</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux, France; Pediatric Oncology Hematology Unit, University Hospital, Plurithématique CIC (CICP), Centre d'Investigation Clinique (CIC) 1401, INSERM Bordeaux. nathalie.aladjidi@chu-bordeaux.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Haematologica</MedlineTA>
        <NlmUniqueID>0417435</NlmUniqueID>
        <ISSNLinking>0390-6078</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536380">Evans Syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000744" MajorTopicYN="Y">Anemia, Hemolytic, Autoimmune</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013921" MajorTopicYN="N">Thrombocytopenia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>14</Day>
          <Hour>4</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33440924</ArticleId>
        <ArticleId IdType="pmc">PMC8804581</ArticleId>
        <ArticleId IdType="doi">10.3324/haematol.2020.271106</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Aladjidi N, Fernandes H, Leblanc T, et al. . Evans syndrome in children: long-term outcome in a prospective French national observational cohort. Front Pediatr. 2015;3:79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4586429</ArticleId>
            <ArticleId IdType="pubmed">26484337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans RS, Takahashi K, Duane RT, Payne R, Liu C.
Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med. 1951;87(1):48-65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14782741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathew P, Chen G, Wang W.
Evans syndrome: results of a national survey. J Pediatr. Hematol Oncol. 1997;19(5):433-437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9329465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pui CH, Wilimas J, Wang W.
Evans syndrome in childhood. J. Pediatr. 1980;97(5):754–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7191890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savaşan S, Warrier I, Ravindranath Y.
The spectrum of Evans’ syndrome. Arch Dis Child. 1997;77(3):245-248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1717303</ArticleId>
            <ArticleId IdType="pubmed">9370906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang WC. Evans syndrome in childhood: pathophysiology, clinical course, and treatment. Am J Pediatr Hematol Oncol. 1988;10(4):330-338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3071168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blouin P, Auvrignon A, Pagnier A, et al. . Syndrome d’Evans : étude rétrospective de la société d’hématologie et d’immunologie pédiatrique (36 cas). Arch Pédiatrie. 2005;12(11):1600-1607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16185853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aladjidi N, Leverger G, Leblanc T, et al. . New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96(5):655-663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3084911</ArticleId>
            <ArticleId IdType="pubmed">21228033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannering N, Hansen DL, Frederiksen H.
Evans syndrome in children below 13 years of age – a nationwide population-based cohort study. PoS One. 2020; 15(4):e0231284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7145102</ArticleId>
            <ArticleId IdType="pubmed">32271826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pincez T, Neven B, Le Pointe HD, et al. . Neurological involvement in childhood Evans syndrome. J Clin Immunol. 2019; 39(2):171-181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30671780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costallat GL, Appenzeller S, Costallat LTL. Evans syndrome and systemic lupus erythematosus: clinical presentation and outcome. Joint Bone Spine. 2012;79(4):362-364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21944976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teachey DT, Manno CS, Axsom KM, et al. . Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105(6):2443-2448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15542578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjadj J, Aladjidi N, Fernandes H, et al. . Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood. 2019;134(1):9-21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30940614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White PH, Cooley WC, Group TCRA, et al. . Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics. 2018;142(5):e20182587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30348754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodeghiero F, Stasi R, Gernsheimer T, et al. . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19005182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petri M, Orbai A-M, Alarcón GS, et al. . Derivation and validation of Systemic Lupus International Collaborating Clinics Classification Criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3409311</ArticleId>
            <ArticleId IdType="pubmed">22553077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira JB, Bleesing JJ, Dianzani U, et al. . Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35-40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2953894</ArticleId>
            <ArticleId IdType="pubmed">20538792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ducassou S, Gourdonneau A, Fernandes H, et al. . Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. Br J Haematol. 2020;189(5):931-942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32130726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rieux-Laucat F, Le Deist F, Fischer A.
Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10(1):124-133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12655301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert D, Bode C, Kenefeck R, et al. . Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410-1416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4668597</ArticleId>
            <ArticleId IdType="pubmed">25329329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan SE, Haapaniemi E, Russell MA, et al. . Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 2014;46(8):812-814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4129488</ArticleId>
            <ArticleId IdType="pubmed">25038750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Besnard C, Levy E, Aladjidi N, et al. . Pediatric-onset Evans syndrome: heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. Clin Immunol. 2018;188:52-57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29330115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwab C, Gabrysch A, Olbrich P, et al. . Phenotype, penetrance, and treatment of 133 CTLA-4-insufficient individuals. J. Allergy Clin Immunol. 2018;142(6):1932-1946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6215742</ArticleId>
            <ArticleId IdType="pubmed">29729943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neven B, Magerus-Chatinet A, Florkin B, et al. . A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011; 118(18):4798-4807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21885602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonilla FA, Barlan I, Chapel H, et al. . International Consensus Document (ICON): common variable immunodeficiency disorders. J. Allergy Clin Immunol Pract. 2016;4(1):38-59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4869529</ArticleId>
            <ArticleId IdType="pubmed">26563668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarvin SE, O’Neil KM. Systemic lupus erythematosus, Sjögren syndrome, and mixed connective tissue disease in children and adolescents. Pediatr Clin North Am. 2018; 65(4):711-737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30031495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lube GE, Ferriani MPL, Campos LMA, et al. . Evans syndrome at childhood-onset systemic lupus erythematosus diagnosis: a large multicenter study. Pediatr Blood Cancer. 2016;63(7):1238-1243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27018636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miano M. How I manage Evans Syndrome and AIHA cases in children. Br J Haematol. 2016;172(4):524-534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26625877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Moon JS, Lee C-R, et al. . Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J. Allergy Clin Immunol. 2016;137(1):327-330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26478010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo B, Zhang K, Lu W, et al. . Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436-440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26206937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klemann C, Esquivel M, Magerus-Chatinet A, et al. . Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome. Haematologica. 2017;102(2):e52-e56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5286954</ArticleId>
            <ArticleId IdType="pubmed">27789675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel M, Chanet V, Dechartres A, et al. . The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009; 114(15):3167-3172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19638626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabriel P, McManus M, Rogers K, White P.
Outcome evidence for structured pediatric to adult health care transition interventions: a systematic review. J Pediatr. 2017; 188:263-269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28668449</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
